Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc. (AXSM)
NASDAQ:AXSM
Total Valuation
Axsome Therapeutics has a market cap or net worth of $7.98B. The enterprise value is $7.90B.
Market Cap$7.98B
Enterprise Value$7.90B
Share Statistics
Axsome Therapeutics has 51,153,290 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,153,290
Owned by Insiders15.71%
Owned by Institutions11.78%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -2.07 and return on invested capital (ROIC) is -43.95%.
Return on Equity (ROE)-2.07
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-43.95%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee896.76K
Profits Per Employee-257.27K
Employee Count712
Asset Turnover0.93
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is ―. Axsome Therapeutics’s PEG ratio is 1.29.
PE Ratio―
PS Ratio14.23
PB Ratio102.90
Price to Fair Value102.90
Price to FCF-97.27
Price to Operating Cash Flow-84.61
PEG Ratio1.29
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 638.50M and earned -183.17M in profits. Earnings per share was -3.68.
Revenue638.50M
Gross Profit591.02M
Operating Income-169.24M
Pretax Income-183.70M
Net Income-183.17M
EBITDA-168.08M
Earnings Per Share (EPS)-3.68
Cash Flow
In the last 12 months, operating cash flow was -93.41M and capital expenditures -409.00K, giving a free cash flow of -93.81M billion.
Operating Cash Flow-93.41M
Free Cash Flow-93.81M
Free Cash Flow per Share-1.83
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change24.19%
50-Day Moving Average175.97
200-Day Moving Average135.93
Relative Strength Index (RSI)33.24
Average Volume (3m)581.40K
Important Dates
Axsome Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateFeb 23, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Axsome Therapeutics as a current ratio of 1.55, with Debt / Equity ratio of 273.28%
Current Ratio1.55
Quick Ratio1.48
Debt to Market Cap0.02
Net Debt to EBITDA0.49
Interest Coverage Ratio-25.81
Taxes
In the past 12 months, Axsome Therapeutics has paid -530.00K in taxes.
Income Tax-530.00K
Effective Tax Rate<0.01
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -53.57, with an EV/FCF ratio of -96.40.
EV to Sales14.10
EV to EBITDA-53.57
EV to Free Cash Flow-96.40
EV to Operating Cash Flow-96.40
Balance Sheet
Axsome Therapeutics has $322.93M in cash and marketable securities with $241.29M in debt, giving a net cash position of $81.64M billion.
Cash & Marketable Securities$322.93M
Total Debt$241.29M
Net Cash$81.64M
Net Cash Per Share$1.60
Tangible Book Value Per Share$0.72
Margins
Gross margin is 92.56%, with operating margin of -26.51%, and net profit margin of -28.69%.
Gross Margin92.56%
Operating Margin-26.51%
Pretax Margin-28.77%
Net Profit Margin-28.69%
EBITDA Margin-26.32%
EBIT Margin-27.74%
Analyst Forecast
The average price target for Axsome Therapeutics is $221.87, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$221.87
Price Target Upside42.15% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast65.83%
EPS Growth Forecast28.50%